PT-141 (bremelanotide) for women and men: what the trials measured

Reviewed 18 sourcesPublished by PepVault

Bremelanotide (PT-141, Vyleesi): what the RECONNECT trials measured in women, the label's 40% nausea rate, and the small erection studies that exist in men.

A couple walking hand in hand on a beach
Last reviewed
Sources
18
Questions
6
Compounds
2

The short answer

PT-141 is bremelanotide, approved by the FDA in June 2019 as Vyleesi for premenopausal women with acquired, generalized low sexual desire that causes distress. In two phase 3 trials of 1,267 women, it raised a 1.2-to-6 desire score by about 0.35 points more than placebo, did not add satisfying sexual events, and caused nausea in 40%. In men, only small early studies exist.

Every number checked at its primary source · · 18 sources · How we research

Evidence: Approved drug in women: two phase 3 trials in 1,267 premenopausal women with HSDD, a 327-woman phase 2b and a 52-week open-label extension. In men: small early erection studies only, none phase 3.

A couple walking hand in hand on a beach

What is PT-141 approved for?

Bremelanotide is a ring-shaped peptide of 7 amino acids, a close cousin of melanotan II, that switches on the body's melanocortin receptors19. The FDA approved it as Vyleesi on June 21, 20192. The label covers one group only: premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD1.

  • Hypoactive sexual desire disorder: low sexual desire that causes marked distress or trouble in a relationship, and is not explained by another medical or mental health condition, problems in the relationship, or a medicine1.
  • Acquired: the low desire began after a time with no problems1.
  • Generalized: it happens whatever the situation or partner1.

The label also says what Vyleesi is not for: HSDD after menopause, HSDD in men, and enhancing sexual performance1. It is a melanocortin receptor agonist, a drug that switches these receptors on, and it acts mainly at MC1R and MC4R at the approved dose; MC4R sits on nerve cells across the brain, and the label states that how it improves desire is unknown1. It does not work by sending more blood to the genitals, which is how pills like sildenafil work.

The label's dose is 1.75 mg, injected under the skin of the belly or thigh with a single-dose autoinjector, at least 45 minutes before expected sexual activity, as needed1. The label's limits are no more than one dose in 24 hours and no more than 8 doses a month, and it says to stop after 8 weeks if there is no improvement1. Those are the label's terms; the prescriber sets any treatment.

Try it

How PT-141 builds up

An estimate from a half-life of about 2.7 hours, one dose a day for four weeks. The shape of the level, not a measurement.

Try your own schedulePT-141 in the library

The curve uses the label's mean half-life of about 2.7 hours after an injection under the skin (range 1.9 to 4.0), with blood levels peaking at about 1 hour1. The label adds that how long each dose works is not known1.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault adds PT-141 as an as-needed compound: you log each dose when you take it, with no schedule and no missed-dose marks. Nausea, flushing or a headache can go on the Side effects page against that day.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What did the RECONNECT trials measure?

RECONNECT was two identical phase 3 trials, Study 301 and Study 302, run from 2015 to 2016, almost all at US sites31516. They randomized 1,267 premenopausal women with HSDD of at least 6 months to the 1.75 mg autoinjector or a placebo (dummy) injection, used as needed for 24 weeks; most used it two to three times a month13.

Both main measures were questionnaires. The desire score adds two questions on how often and how strongly a woman felt desire over the past 4 weeks, and runs from 1.2 to 6. The distress score is one question, how often she felt bothered by low desire, scored 0 (never) to 4 (always)1. A secondary measure counted satisfying sexual events a month1.

Measure (scale)Study 301: drug vs placeboStudy 302: drug vs placeboResult
Desire score (1.2 to 6), mean change+0.5 vs +0.2+0.6 vs +0.2Better on the drug in both1
Distress over low desire (0 to 4), mean change−0.7 vs −0.4−0.7 vs −0.4Better on the drug in both1
Satisfying sexual events a month, mean change0.0 vs −0.10.0 vs 0.0No difference1
Stopped the 24 weeks early40% vs 13%39% vs 25%More stopped on the drug1

Pooled across both trials, the gain over placebo was 0.35 points on the desire score and 0.33 points less distress3. The women started near 2 on the 1.2-to-6 desire scale; the drug group's average rose about half a point, and the placebo group's rose 0.21.

Of the 856 women who finished the 24 weeks, 684 went on to a 52-week open-label extension, where everyone knew they were on the drug, and 272 completed it4. Desire scores in women who had been on bremelanotide from the start rose 1.25 to 1.30 points from where they began, with no new safety signals4. With no placebo group in that phase, those numbers show who stayed and how they rated themselves, not the drug's effect alone.

How big is the benefit?

The label calls the gains statistically significant. The dose-finding trial before RECONNECT, in 327 women, had also found more satisfying events with the 1.25 and 1.75 mg doses pooled: +0.7 a month against +0.2 on placebo over 12 weeks5. In RECONNECT that measure did not move1.

Independent researchers read the same data more critically. A 2021 re-analysis of the FDA application found results close to the published ones, but also that the odds of quitting over side effects were about 12 times higher on the drug, and that fewer women on it both finished the trial and chose to continue into the extension7. A 2024 follow-up analysed 8 of the trials' 11 registered efficacy measures that had never been published, and found effects from nil to small; it also found little evidence that the trials' questionnaires are valid in HSDD8. The sponsor's own safety review gives the same direction in plain numbers: 70% of the drug group went on to the extension, against 87% on placebo6.

Across a group, the effect on desire and distress is measurable and modest, and many women stopped early. The label's answer for each woman is its 8-week rule: stop if there is no improvement1.

What side effects does the label list?

Side effectVyleesi (627 women)Placebo (620 women)
Nausea40.0%1.3%
Flushing20.3%0.3%
Injection site reactions13.2%8.4%
Headache11.3%1.9%
Vomiting4.8%0.2%
Cough3.3%1.3%
Fatigue3.2%0.5%

These are the label's pooled phase 3 rates; most events were mild or moderate and short-lived1. Nausea starts within about an hour of the dose and lasts about 2 hours. It is highest with the first dose, in 21% of women, and about 3% with later doses1. In the trials, 13% took an anti-nausea medicine and 8% stopped because of nausea1. In a study of 228 women, taking ondansetron, a common anti-nausea tablet, 30 minutes before did not lower the nausea rate1.

Each dose raises blood pressure a little, by up to 6 mmHg systolic and 3 diastolic at 2 to 4 hours, and slows the heart by up to 5 beats a minute; both are usually back to baseline within 12 hours1. The label does not allow it with uncontrolled high blood pressure or known heart disease1. Through MC1R, the tanning receptor, it can darken small patches of skin, on the face, gums or breasts: in 1% of women at up to 8 doses a month, and in 38% after 8 daily doses in a separate study1. The patches did not always fade after stopping1.

The label also notes that it slows stomach emptying, which can reduce how well some tablets are absorbed, and that it can sharply lower blood levels of naltrexone taken by mouth, so it is avoided with oral naltrexone products for alcohol or opioid addiction1. Because animal studies in dogs showed harm to the fetus, the label advises effective contraception while taking it and stopping it if pregnancy is suspected1.

Commonly reported: a noticeable rise in desire and arousal an hour or so after a dose (men often describe firmer or spontaneous erections), nausea that is often worst with the first dose, facial flushing, and headache on dosing days.

PepVault adds PT-141 as an as-needed compound: you log each dose when you take it, with no schedule and no missed-dose marks. Nausea, flushing or a headache can go on the Side effects page against that day. Log it in PepVault

When to get help Nausea or vomiting that does not settle, or skin changes that concern you, are reasons to talk to the prescriber, who can also check that your blood pressure is well controlled1.

Does PT-141 work in men?

It has been tested in far fewer men, in shorter studies, and the label excludes men1. Bremelanotide came from melanotan II, which was tested for erectile dysfunction, and it was first given to men as a nasal spray910. The early men's studies measured erections in the clinic with RigiScan, a gauge worn on the penis, sometimes with erotic video, and not desire over months, as RECONNECT did101112.

StudyWho and how manyForm and study doseWhat it found
Diamond 200410Healthy men and men with mild to moderate erectile dysfunction who responded to Viagra; group sizes not stated in the paper's summaryNasal spray, single dosesErections beat placebo at doses above 7 mg, the first one after about 30 minutes
Rosen 200411Healthy men, then men whose erections responded poorly to 100 mg Viagra; group sizes not stated in the paper's summaryInjection under the skin, 0.3 to 10 mg; 4 or 6 mg in the patientsErections beat placebo above 1 mg in healthy men and at both doses in the patients
Diamond 20051219 men with erectile dysfunction who responded to Viagra or Levitra7.5 mg nasal plus 25 mg sildenafil, crossoverThe pair produced more erection than sildenafil alone
Safarinejad 200813342 married men aged 28 to 59 for whom sildenafil had not worked10 mg nasal, at least 16 attempts at home33.5% had a positive result vs 8.5% on placebo; under an expression of concern since 2023

The largest men's trial, the 342-man study from Tehran, has carried an expression of concern from its journal since January 2023, which means the editors have flagged questions about it, so its result is the least secure part of the men's evidence13. A 2026 systematic review of peptides for male sexual function found 12 studies with 372 men across every peptide it covered, and judged the evidence limited by small samples and short follow-up14. No phase 3 trial of bremelanotide in men has been published, and a ClinicalTrials.gov search in November 2026 found none registered; every bremelanotide trial there for sexual function enrolled women.

Most men's doses were nasal sprays, which deliver differently from the label's injection, so those numbers are what was tested, not a dose that carries over110.

What is being tested next?

Palatin, its developer, has tested bremelanotide for weight with tirzepatide, the drug in Mounjaro and Zepbound17. After 4 weeks of tirzepatide alone, adults with obesity took the pair, either drug alone, or placebo for 4 more weeks. In a March 2025 press release, Palatin reported 4.4% weight loss on the pair against 1.6% on placebo over the 8 weeks18. These are the company's own topline numbers; as of November 2026 none are on the registry or in a journal17.

Track it in the app

Sources

  1. Vyleesi (bremelanotide injection) prescribing information. Cosette Pharmaceuticals. Revised October 2026; DailyMed version 2, November 9, 2026. dailymed.nlm.nih.gov
  2. Drugs@FDA: NDA 210557, Vyleesi, original approval June 21, 2019. accessdata.fda.gov
  3. Kingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019. PubMed 31599840
  4. Simon JA et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019. PubMed 31599847
  5. Clayton AH et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016. PubMed 27181790
  6. Clayton AH et al. Safety profile of bremelanotide across the clinical development program. J Womens Health. 2022. PubMed 35147466
  7. Spielmans GI. Re-analyzing phase III bremelanotide trials for "hypoactive sexual desire disorder" in women. J Sex Res. 2021. PubMed 33678061
  8. Spielmans GI, Ellefson EM. Small effects, questionable outcomes: bremelanotide for hypoactive sexual desire disorder. J Sex Res. 2024. PubMed 36809187
  9. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006. PubMed 16412534
  10. Diamond LE et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141 in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004. PubMed 14963471
  11. Rosen RC et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141 in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004. PubMed 14999221
  12. Diamond LE et al. Co-administration of low doses of intranasal PT-141 and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005. PubMed 15833522
  13. Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008 (expression of concern, 2023). PubMed 18206919
  14. Ramez M et al. Peptides for male sexual dysfunction: a systematic review of emerging evidence. J Sex Med. 2026. PubMed 43002584
  15. ClinicalTrials.gov NCT02333071: bremelanotide in premenopausal women with HSDD (Study 301). Palatin Technologies. clinicaltrials.gov
  16. ClinicalTrials.gov NCT02338960: bremelanotide in premenopausal women with HSDD (Study 302). Palatin Technologies. clinicaltrials.gov
  17. ClinicalTrials.gov NCT06565611: bremelanotide co-administered with tirzepatide for obesity, phase 2. Palatin Technologies. clinicaltrials.gov
  18. Palatin Technologies. Press release: MC4R agonist bremelanotide co-administered with tirzepatide meets primary endpoint in phase 2 obesity study. March 31, 2025. palatin.com

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo